Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness.
暂无分享,去创建一个
P. Prorok | B. Kramer | H. Welch | A. J. O’Malley | Barnett S. Kramer | H. Gilbert Welch | A. James O’Malley | H. G. Welch
[1] R. Carlson. Lymph Node Status Losing Importance in Breast Cancer , 2011 .
[2] D. Kopans. Arguments against mammography screening continue to be based on faulty science. , 2014, The oncologist.
[3] H. Welch,et al. The natural history of invasive breast cancers detected by screening mammography. , 2008, Archives of internal medicine.
[4] B. Møller,et al. Effect of organised mammography screening on stage-specific incidence in Norway: population study , 2016, British Journal of Cancer.
[5] P. Gøtzsche,et al. Effect of screening mammography on breast cancer incidence. , 2013, The New England journal of medicine.
[6] Anne Marie Murphy,et al. Beyond the mammography quality standards act: measuring the quality of breast cancer screening programs. , 2014, AJR. American journal of roentgenology.
[7] X. Castells,et al. Mammographic and clinical characteristics of different phenotypes of screen-detected and interval breast cancers in a nationwide screening program , 2015, Breast Cancer Research and Treatment.
[8] J. Elmore,et al. Projecting the benefits and harms of mammography using statistical models: proof or proofiness? , 2015, Journal of the National Cancer Institute.
[9] D. Berry,et al. Effect of screening and adjuvant therapy on mortality from breast cancer , 2005 .
[10] Anthony B. Miller,et al. Why have breast cancer mortality rates declined , 2015 .
[11] H. Gilbert Welch,et al. Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence , 2013 .
[12] Mitchell H Gail,et al. Improvements in US Breast Cancer Survival and Proportion Explained by Tumor Size and Estrogen-Receptor Status. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] R. Merrill,et al. How representative are the surveillance, epidemiology, and end results (SEER) Program cancer data of the United States? , 2004, Cancer Causes & Control.
[14] R. Blanks,et al. Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990-8: comparison of observed with predicted mortality , 2000, BMJ : British Medical Journal.
[15] B. Hankey,et al. Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. , 1995, Cancer.
[16] Marvin Zelen,et al. Effect of screening mammography on breast-cancer mortality in Norway. , 2010, The New England journal of medicine.
[17] Klim McPherson,et al. Observational intensity bias associated with illness adjustment: cross sectional analysis of insurance claims , 2013, BMJ : British Medical Journal.
[18] S. Duffy,et al. Quantification of the effect of mammographic screening on fatal breast cancers: The Florence Programme 1990–96 , 2002, British Journal of Cancer.
[19] P. Prorok,et al. Lead time and overdiagnosis. , 2014, Journal of the National Cancer Institute.
[20] Russell P. Harris,et al. Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods , 2015, BMJ : British Medical Journal.
[21] K. Rostgaard,et al. Why did the breast cancer lymph node status distribution improve in Denmark in the pre-mammography screening period of 1978–1994? , 2010, Acta oncologica.
[22] Per-Henrik Zahl DrMedSci,et al. Lead-Time Models Should Not Be Used to Estimate Overdiagnosis in Cancer Screening , 2014, Journal of General Internal Medicine.
[23] Laura Esserman,et al. Rethinking screening for breast cancer and prostate cancer. , 2009, JAMA.
[24] Rediet Abebe,et al. Breast Cancer Screening, Incidence, and Mortality Across US Counties. , 2015, JAMA internal medicine.
[25] Virginia G Kaklamani,et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. , 2015, The New England journal of medicine.
[26] C. Hudis. Biology before Anatomy in Early Breast Cancer--Precisely the Point. , 2015, The New England journal of medicine.
[27] P. Gøtzsche,et al. Lead-Time Models Should Not Be Used to Estimate Overdiagnosis in Cancer Screening , 2014, Journal of general internal medicine.
[28] D. Berry. Impact of screening mammography on breast cancer mortality , 2016 .
[29] H. Welch,et al. Trends in Metastatic Breast and Prostate Cancer--Lessons in Cancer Dynamics. , 2015, The New England journal of medicine.